Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $563
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsPrice TargetHot
Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $500 to $563.
Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $500 to $563.